Keryx Biopharmaceuticals (KERX) Earning Somewhat Positive Media Coverage, Study Shows
News headlines about Keryx Biopharmaceuticals (NASDAQ:KERX) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Keryx Biopharmaceuticals earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.2176411044747 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern’s scoring:
- Keryx Biopharmaceuticals, Inc. (KERX) Downgraded to Sell at Zacks Investment Research (americanbankingnews.com)
- Technical Reports on Biotech Equities — Celgene, Dynavax Technologies, Keryx Biopharma, and Moleculin Biotech – Markets Insider (markets.businessinsider.com)
- Watching the Tape Move for Keryx Biopharmaceuticals Inc (KERX) and Brunswick Corp (BC) – FLBC News (flbcnews.com)
- Oscillating Volume stocks-:- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) – Market Breaking Point (press release) (journalfinance.net)
- Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017 – GlobeNewswire (press release) (globenewswire.com)
A number of research analysts have recently issued reports on KERX shares. Maxim Group lifted their target price on shares of Keryx Biopharmaceuticals from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Monday, May 15th. ValuEngine cut shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a research note on Saturday, June 17th. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a research note on Wednesday, July 12th. Finally, BidaskClub cut shares of Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. Keryx Biopharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $7.48.
Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 7.32 on Tuesday. The company’s market cap is $869.25 million. The company has a 50-day moving average of $7.01 and a 200 day moving average of $6.44. Keryx Biopharmaceuticals has a 52-week low of $4.11 and a 52-week high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.60. The firm had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The business’s revenue was up 62.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.42) EPS. Equities research analysts predict that Keryx Biopharmaceuticals will post ($1.23) EPS for the current year.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.